Habib J Dable has sold XLRN and made no open-market buys since Dec 2018

Habib J. Dable is a biopharmaceutical executive and former President and Chief Executive Officer of Acceleron Pharma Inc., where he led the company’s transition from a primarily research-focused biotechnology firm to a commercial-stage enterprise and oversaw its growth to more than 400 employees.( During his tenure at Acceleron, he guided the launch of the company’s first blockbuster product in 2019, consistently outperformed the biotech index in stock performance, and ultimately helped generate more than $10 billion in shareholder value through the company’s sale to Merck & Co. in 2021.( As CEO and President, he also served as the reporting corporate insider for Acceleron Pharma Inc. (ticker: XLRN), executing equity transactions disclosed in SEC filings, including share sales reported in early 2021.(

Dable’s career spans nearly three decades in the pharmaceutical and biotechnology industry, beginning in sales and progressing to senior leadership roles, including President of Bayer’s U.S. Pharmaceuticals organization before joining Acceleron.( He has been recognized by Institutional Investor Magazine as a top-ranked smid-cap biotech CEO for three consecutive years (2019–2021) and was named one of “Pharma’s Emerging Leaders” by Pharmaceutical Executive Magazine in 2016.( Following his time at Acceleron, he has continued to contribute to the sector as a board member and advisor to multiple biopharmaceutical companies, leveraging his global experience across cardiovascular, hematology, neurology, oncology, and other therapeutic areas.(

Written by Perplexity from public sources.